DDrare: Database of Drug Development for Rare Diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
97	潰瘍性大腸炎	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03235752 (ClinicalTrials.gov)	February 6, 2018	28/7/2017	Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis	A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients With Active Ulcerative Colitis	Active Ulcerative Colitis	Drug: TJ301 300mg;Drug: TJ301 600mg;Drug: Placebo	I-Mab Biopharma HongKong Limited	NULL	Recruiting	18 Years	70 Years	All	90	Phase 2	Australia;China;Korea, Republic of;Taiwan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03235752
(ClinicalTrials.gov)

February 6, 2018

28/7/2017

Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of TJ301 (FE 999301) Administered Intravenously in Patients With Active Ulcerative Colitis

Active Ulcerative Colitis

Drug: TJ301 300mg;Drug: TJ301 600mg;Drug: Placebo

I-Mab Biopharma HongKong Limited

NULL

Recruiting

18 Years

70 Years

All

Phase 2

Australia;China;Korea, Republic of;Taiwan